Notice Type
Departmental
Notice Title

Notice of Application to Register a Trade Name Product (Notice No. MPI ACVM 14)

Notice is given under section 14(1) of the Agricultural Compounds and Veterinary Medicines Act 1997 (“Act”), of the following application to register a trade name product under section 9(1) of the Act:

Trade Name: Purevax 3

Reference: A012115

Active Ingredients and Concentrations:

Each 1ml (0.5mL) dose contains:
Attenuated feline rhinotracheitis herpesvirus (FHV F2 strain) ≥ 104.9 CCID50
Inactivated feline calicivirus (FCV 421 and FCV G1 strains) ≥ 2.0 ELISA U.
Attenuated feline panleukopenia virus (PLI IV) ≥ 103.5 CCID50

Formulation Type: Lyophilisate with aqueous diluent

Application Method/Administration Route: Subcutaneous

Use Claim:

For active immunization of cats aged 8 weeks and older:

        • Against feline viral rhinotracheitis to reduce clinical signs,
        • Against calicivirus infection to reduce clinical signs,
        • Against feline panleukopenia to prevent mortality and clinical signs.

Any person may make a written submission to the director-general concerning this application.

Under sections 16 and 17 of the Act, a written submission:

  1. must state in full the reasons for making the submission;
  2. may state any decision sought on that application; and
  3. must be received by the director-general no later than 30 working days after the date of this notice.

Each submission must state the trade name product(s) to which it relates. Under section 18 of the Act, a copy of every submission will be forwarded to the applicant.

The following address is:

  1. where submissions on this application are to be sent;
  2. where requests for copies of the public information relating to the application can be sent;
  3. where public information relating to the application can be viewed; and
  4. the director-general’s address for service:

ACVM Team, Ministry for Primary Industries, Charles Fergusson Building, 38–42 Bowen Street, Pipitea, Wellington 6011. Postal Address: PO Box 2526, Wellington 6140. Email: acvm.consultation@mpi.govt.nz.

MPI encourages submission by email.

The applicant’s address for service is:

Boehringer Ingelheim Animal Health New Zealand Limited, Level 2, 3 Te Kehu Way, Mount Wellington, Auckland 1060. Postal Address: PO Box 76 211, Manukau, Auckland 2241.

Dated at Wellington this 18th day of July 2024.

SHALEEN NARAYAN, Manager Approvals, Ministry for Primary Industries (acting under delegated authority).